Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was explore the relationship between plasma concentration of angiotensin II (Ang II), Adrenomedulin (ADM) and adrenotensin (ADT) in patients with hypertension and LVH.
|
31217886 |
2019 |
Left Ventricular Hypertrophy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
However, vasodilators and diuretics, which stimulate adrenoceptor activity and increase angiotensin II levels, were found to be less effective in reversing LV hypertrophy.
|
1380616 |
1992 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Five genetic polymorphisms of the RAAS (ACE, AGTR1, AGT, CMA, CYP11B2) were analyzed in all patients and the results of genetic analysis were correlated to severity of AS and LVH to determine the importance of the polymorphisms for LVH.
|
11275936 |
2001 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We determined the B2BKR genotype of 90 patients with essential hypertension and echocardiographically diagnosed LV hypertrophy, included in a double-blind study to receive treatment for 48 weeks with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan or the beta1-adrenoceptor antagonist atenolol.
|
12640257 |
2003 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Eight chronically instrumented pigs receiving continuous angiotensin II infusion during 28days to induce chronic hypertension and LV hypertrophy.
|
29196088 |
2018 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Angiotensinogen gene M235T polymorphism predicts left ventricular hypertrophy in endurance athletes.
|
10440164 |
1999 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The angiotensin II subtype 1 (AT1) receptor antagonist valsartan suppressed the elevated blood pressure completely and left ventricular hypertrophy incompletely, but did not affect the other phenotypes.
|
14620933 |
2003 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, the induction of human cardiac fibroblasts (HCF) and human umbilical vein endothelial cells (HUVEC) with the LVH mediator angiotensin II enabled us to investigate uremic LVH progression in vitro.
|
19094982 |
2009 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Frequency of IT genotype of ATG gene in patients with LVH was significantly (P<0.01) greater than that in normal controls or marginally (P=0.1) higher than that in patients without LVH.
|
10646957 |
2000 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
ACE is responsible for the generation of angiotensin II, which is implicated in the development of left ventricular hypertrophy, an independent risk factor for morbidity and mortality in hypertension.
|
7820539 |
1994 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
1.The relationship between the angiotensinogen (AGT) T174M, angiotensin converting enzyme (ACE) insertion/deletion (I/D) and the angiotensin II type 1 receptor (AT1) genetic markers and left ventricular hypertrophy was examined in normal subjects and those with aortic stenosis.2.
|
8800593 |
1996 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, neither ID ACE-gene polymorphism nor ATI-receptor gene and angiotensinogen gene polymorphism was associated with LVH.
|
11688760 |
2001 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We challenged C57BL/6 adult male mice with an infusion of AngII (osmotic pumps; 2 mg/kg.day) to induce LVH.
|
30267750 |
2018 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Angiotensinogen M235T and T174M polymorphisms have individually been associated with elevated levels of plasma angiotensinogen, hypertension, and left ventricular hypertrophy.
|
17145981 |
2007 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The development of left ventricular hypertrophy in subjects with hypertrophic cardiomyopathy (HCM) is variable, suggesting a role for modifying factors such as angiotensin II.
|
11751703 |
2001 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Polymorphism of the AGT M235T gene but not ACE I/D gene is associated with greater LVMi and relative wall thickness, indicating more concentric LVH, in Chinese peritoneal dialysis patients.
|
12675870 |
2003 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
These trends were also observed in histological analysis, demonstrating that cardiac function tracking using in vivo and real-time 9.4T MR imaging provides valuable information about the cardiac remodeling induced by AngII and sRAGE in an AngII-induced LV hypertrophy mice model.
|
31186521 |
2019 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
We further unraveled robust increases in HCN2/HCN4 transcripts and protein levels, using real-time RT-PCR and Western blot analyses, in a rat model of left ventricular hypertrophy and in angiotensin II-induced neonatal ventricular hypertrophy.
|
19471099 |
2009 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronically instrumented pigs received angiotensin II infusion for4weeks to induce chronic hypertension (133 ± 7 mmHg vs 98 ± 5 mmHg for mean arterial pressure at Day 28 vs 0, respectively) and LV hypertrophy.
|
31051181 |
2019 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiotensin-converting enzyme and angiotensinogen genes in patterns of left ventricular hypertrophy and in diastolic dysfunction.
|
8582095 |
1996 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the beta1-adrenergic receptor blocker atenolol (n = 43).
|
12022239 |
2002 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients.
|
27722772 |
2017 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
The development of left ventricular hypertrophy (LVH) in subjects with hypertrophic cardiomyopathy (HCM) is variable, suggesting a role for modifying factors such as angiotensin II.
|
9822439 |
1998 |
Left Ventricular Hypertrophy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The angiotensinogen T174M and M235T and the AT1-receptor A1166C polymorphisms were related to the change in LVH during antihypertensive treatment with an AT1-receptor antagonist; of these angiotensinogen T174M was the most powerful.
|
11910301 |
2002 |
Left Ventricular Hypertrophy
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the possibility that RAGE-mediated signaling is involved in angiotensin II (Ang II)-induced cardiac left ventricular hypertrophy has yet to be investigated.
|
29796842 |
2018 |